1	Universal PCR for Bacteria, Mycobacteria, and Fungi:					
2	A 10-year Retrospective Review	of Clinical Indications and Patient Outcomes				
3	Jeffrey Kubiak MD, PhD; ^a Alexandra Morgan; ^a Andrea Kirmaier, PhD; ^a					
4	Ramy Arnaout MD, DPhil; ab#† Stefan Riedel MD, PhDa#†					
5	^a Department of Pathology, Beth Israel Deaco	ness Medical Center, Department of Pathology, Boston, MA				
6	02215; ^b Division of Clinical Informatics, Department of Medicine, Beth Israel Deaconess Medical Center,					
7	Boston, MA 02215; ⁺ Co-corresponding autho	rs				
8	#To whom correspondence should be addres	ssed at:				
9	Stefan Riedel	Ramy Arnaout				
10	Department of Pathology	Department of Pathology				
11	BIDMC	BIDMC				
12	330 Brookline Avenue	330 Brookline Avenue				
13	Boston, MA 02215	Boston, MA 02215				
14	sriedel@bidmc.harvard.edu	rarnaout@bidmc.harvard.edu				

15 Running Title: Clinical indications and outcomes of universal PCR

16 Keywords: universal PCR, molecular diagnostics, laboratory utilization, outcomes

17 Abstract

18	Universal PCR for bacteria, mycobacteria, and fungi can aid in the diagnosis of occult infections,
19	especially in the case of fastidious organisms or when prior antimicrobial treatment compromises
20	culture growth. However, the limitations of this technology, including lack of specificity, high cost, long
21	turnaround time, and lack of susceptibility data, may limit its effect on clinical outcomes. We performed
22	a retrospective analysis of all specimens sent for universal PCR over a 10-year period from 2013-2022,
23	focusing on clinical indications for test utilization and patient outcomes. A total of 708 specimens were
24	sent from 638 patients. Of those specimens, 163 were positive, for an overall positivity rate of 23%. Pre-
25	analytic factors associated with a positive universal PCR result were the presence of organisms on Gram
26	stain or histology, the presence of neutrophils on Gram stain, and growth on culture. Positivity rates
27	varied significantly by specimen type. 20% of all organisms detected were deemed contaminants by the
28	clinical services. A positive universal PCR led to a change in antibiotic management in 29% of cases.
29	Positive fungal universal PCR results sent from hospitalized patients were associated with worse
30	outcomes, including increased hospital mortality. Our findings suggest that factors such as the presence
31	of organisms or neutrophils on Gram stain, specimen source/clinical context, and anticipated changes in
32	management based on results should be strongly considered when making stewardship decisions
33	regarding the appropriateness of this testing modality.

34

35 Introduction

36 Universal PCR for bacteria, mycobacteria, and fungi is an attractive technology for the diagnosis of occult 37 infections that may not be detectable by routine microbiology laboratory methods¹. As molecular 38 diagnostics such as these continue to evolve, laboratory stewardship is becoming increasingly important 39 to ensure that these novel technologies are being utilized to maximize benefit to the patient while 40 minimizing unnecessary healthcare costs. Universal PCR is best utilized in cases of culture-negative infections, especially in cases of fastidious 41 42 organisms or when antimicrobials were given prior to specimen collection that compromise culture growth². While universal PCR has a fairly low sensitivity as a standalone $assay^3$, prospective studies have 43 shown that when used in conjunction with culture, the overall detection rate may be enhanced over the 44 45 use of culture alone⁴⁻⁷. Various studies have supported the use of universal PCR in cases of meningitis^{5,8,9}, endophthalmitis^{10,11}, joint and bone infections^{6,12–15}, pleural effusions^{16,17}, fungal 46 47 sinusitis,¹⁸ and endocarditis^{19–22}. While positive universal PCR results have been reported to lead to 48 changes in antimicrobial treatment, there is considerable variability between studies regarding the extent to which these results impact antimicrobial management^{23–25}. 49 Universal PCR is not without its limitations. Due to its non-specific nature, there is a high rate of false-50

positive results from contamination, especially in non-sterile body sites²⁶. Universal PCR also cannot provide antimicrobial susceptibility data, and even in the case of a positive result clinicians must rely on epidemiologic data to guide coverage. In the absence of in-house universal PCR testing capacity, sending specimens to reference laboratories can take a week or longer to return results to the ordering institution, leaving clinicians to rely on empiric coverage of suspected organisms during a critical time in hospitalized patients' care. Lastly, this assay comes at a high cost compared to other routine microbiology testing methods, typically hundreds of dollars²⁷. Some studies have suggested that the

58	combination of the lack of susceptibility data, the high rate of contamination, the sensitivity and faster
59	turnaround time of concurrently submitted routine microbiology assays, and the cost mean that
60	universal PCR provides little to no value to patient management or prognosis ^{28–30} .
61	In this context, we aimed to further address the clinical utility of universal PCR, focusing on patterns of
62	utilization and patient outcomes. We performed a retrospective review of all universal PCR tests sent
63	from our hospital network over a 10-year period and determined the impact of positive universal PCR
64	results on patient antimicrobial management and hospitalized patient outcomes. These data may impart
65	diagnostic and prognostic significance for clinicians to determine the merit of testing for their patients
66	and can ultimately guide stewardship decisions about the use of this technology for challenging
67	diagnostic cases.

68

69 Methods

70 We performed a retrospective chart review for all patients for whom universal PCR testing was ordered 71 from our 743-bed tertiary-care medical center. These orders were placed by both outpatient and 72 inpatient clinical teams, typically in conjunction with the infectious disease consult service. Clinicians 73 had the option to order any combination of bacterial, mycobacterial, or fungal universal PCR based on 74 their clinical judgement of potential etiologies of the patient's infection. All universal PCR orders 75 required review and approval by a clinical director of our institution's microbiology laboratories. The 76 specimens were sent to the University of Washington Molecular Diagnosis Microbiology Section 77 (Seattle, WA). Their test relies on sequencing of the 16S rRNA gene, the 65-kD heat shock protein, or the 78 28S rRNA gene plus internal transcribed spacer regions to broadly detect and speciate bacterial, 79 mycobacterial, and fungal DNA sequences, respectively. In the case of bacterial and fungal universal

PCR, reflex testing to next-generation sequencing was included in cases where multiple templates were
 present.

82	We queried our institution's clinical data repository to retrieve information on all specimens ordered for
83	universal PCR from our electronic medical record network over the 10-year period from January 2013
84	through November 2022. A chart review was performed on all patients to determine patient factors and
85	outcomes, including demographic data, relevant clinical laboratory data including concurrent Gram stain
86	results and culture results, specimen type, clinical indications, antibiotic treatment decisions, inpatient
87	status, and hospitalization outcomes. We considered other laboratory tests to be concurrent with the
88	specimen sent for universal PCR if either the same specimen was utilized for both assays or if both
89	specimens were retrieved from the same location during the same surgical procedure. We relied on
90	clinical judgement by physicians treating the patient to determine if a detected organism was
91	considered clinically relevant or a presumed contaminant.
92	All analyzes were neutring D 2 E 1 (D Esymdetics for Statistical Computing Vienne, Austria) and
	All analyses were performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and
93	RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to
93 94	RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test,
93 94 95	RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test, odds ratio, or unpaired Student's T-test was used for comparisons. P values were then corrected for
93 94 95 96	All analyses were performed using K 3.5.1 (K Foundation for Statistical Computing, Vienna, Austria) and RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test, odds ratio, or unpaired Student's T-test was used for comparisons. P values were then corrected for multiple comparisons using the Benjamini-Hochberg method and a corrected p value of <0.05 was
93 94 95 96 97	All analyses were performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austra) and RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test, odds ratio, or unpaired Student's T-test was used for comparisons. P values were then corrected for multiple comparisons using the Benjamini-Hochberg method and a corrected p value of <0.05 was considered to be statistically significant. The Beth Israel Deaconess Medical Center Institutional Review
93 94 95 96 97 98	All analyses were performed using R 3.5.1 (R Foundation for Statistical Computing, Vienna, Austria) and RStudio 1.1.463 (Posit, Boston, MA). Population proportion confidence intervals were calculated to determine 95% confidence intervals for PCR positivity rates for different populations. A chi-squared test, odds ratio, or unpaired Student's T-test was used for comparisons. P values were then corrected for multiple comparisons using the Benjamini-Hochberg method and a corrected p value of <0.05 was considered to be statistically significant. The Beth Israel Deaconess Medical Center Institutional Review Board reviewed the study protocol and determined it to be exempt (protocol no. 2017D000478).

99

100 Results

Over the 10-year period from January 2013 to November 2022, a total of 708 specimens from 638
patients were sent to our reference laboratory for universal PCR. Of those, 574 were tested for bacteria,

103 321 for mycobacteria, and 294 for fungi. Universal PCR specimens had an average turnaround time of 12 104 days from order to result. The overall positivity rate was 23% (163/708, 95% CI 20-26%). The positivity 105 rate for those tested for bacteria was 19% (109/574, 95% CI 16-22%), for mycobacteria was 6% (18/321, 95% CI 3.1-8.1%), and for fungi was 14% (40/294, 95% CI 9.7-18%) (Figure 1A). 106 107 We examined whether other laboratory tests performed on specimens sent for universal PCR were 108 associated with a positive PCR result (**Table 1**), including Gram stain results and results of concurrent 109 histopathology slides examined in surgical pathology. The presence of organisms on Gram stain (23/44 110 positive, 52% [95% CI 38-67%]) was associated with positive universal PCR results (p<0.05) and the 111 absence of neutrophils on Gram stain (29/207 positive, 14% [95% CI 9-19%]) was negatively associated 112 with positive universal PCR results (p<0.05). We observed no significant difference in positivity rate 113 between paraffin-embedded blocks and fresh frozen tissue. However, the presence of organisms seen 114 on histology slides (34/73 positive, 47% [95% CI 35-58%]) was also significantly associated with a positive universal PCR result (p<0.05). The presence of granulomata on histology was not associated with a 115 116 positive PCR result.

Specimens sent for universal PCR had concurrent cultures taken in 656 cases (93%), with 154/656 (23%) of those cultures positive for an organism. Having a culture positive for any organism was significantly associated with positive universal PCR results (53/154 positive, 34% [95% CI 27-42%], p<0.05). Of those cases with a positive culture and positive universal PCR result, there was concordance between those results for organism identification in 36/53 (68%) of cases.

122 A variety of specimen types were sent for universal PCR analysis. These included: artery,

bronchoalveolar lavage, bone, brain (including dura and meninges), breast, cerebrospinal fluid, digits,

124 intervertebral disc, epidural tissue, foreign bodies, joints, liver, lung, lymph node, pericardium,

125 peritoneum, pleura, skin, soft tissue/muscle, heart valves, vitreous, esophagus, fallopian tube, bowel,

bone marrow, uterus, and myocardium. Joint and bone tissue specimens were most frequent, with 165

127 and 148 specimens sent, respectively. Specimen types varied considerably in the overall positivity rates

128 (Figure 1B, Supplemental Table 1). The highest positivity rates were seen in bronchoalveolar lavage

129 specimens (5/8, 63% [95% CI 29%-96%]) and heart valves (11/19, 58% [95% CI 36%-80%]), and the

130 lowest positivity rate was seen with pericardial specimens (0/9, 0%).

131 Likewise, clinical indications for testing varied considerably. The clinical indications for testing included:

132 osteomyelitis, septic arthritis, abscess, granulomata seen on surgical pathology, mass/lesion,

endocarditis, pneumonia, cellulitis, lymphadenopathy, pericardial or pleural effusion, arteritis,

meningitis, peritonitis, sinusitis, aplastic anemia, endophthalmitis, or a non-healing surgical wound. The

highest positivity rate was noted for endocarditis (11/23 positive, 48%, [95% CI 27-68%]). A complete

table of positivity rates for specimen sources broken down by clinical indication and pathogen type can

137 be found in **Supplemental Table 1**.

138 76% of all patients with positive universal PCR results were on empiric antimicrobial therapy prior to 139 receiving results of the assay. Following the reporting of universal PCR results to the online medical 140 record, clinicians considered the universal PCR result to be a contaminating organism in 33/163 (20%, 141 95% CI 14-26%) cases (Figure 2A). When broken down by specimen type, bronchoalveolar lavage (BAL) 142 specimens were considered to have the highest contamination rate, with 4/5 (80%, 95% CI 45-100%) 143 positive PCRs considered to be the result of a contaminant (Figure 2B). 48/163 (29%, 95% CI 22-36%) 144 positive results led to a change in antimicrobial management. Positive results led to a change in 145 antibiotic management in 5/5 cases (100%) of intervertebral discs and 8/11 (72%, 95% CI 46-98%) of 146 heart valves, while certain specimen types such as liver, brain, and BAL did not have any results lead to a 147 change in patient management. Reasons that antimicrobial management was not changed include the 148 patient already being on appropriate empiric therapy (68/163, 42% [95% CI 34%-50%]), the patient 149 improving without antibiotic intervention (8/163, 5% [95% CI 2-8%]), awaiting mycobacterial

susceptibility results from a concurrently submitted culture (2/163, 2% [95% CI 0-4%]), or patient

discharge to hospice or death prior to return of the results (4/163, 3% [95% CI 1-5%]).

152 Finally, we determined whether a positive universal PCR result was associated with particular

153 hospitalization outcomes. Of the 708 total specimens, 593 were from inpatients and 115 were from

154 outpatients, with 136/593 (23%, 95% CI 16-31%) and 27/115 (23%, 95% CI 20-26%) being positive,

respectively. From the time of specimen collection, universal PCR results from inpatients took an

average of 12 days to return, and 76% (95% CI 72%-79%) of the results returned after the patient was

discharged from the hospital. Among inpatients who were tested via universal PCR, 13/593 (2%, 95% CI

158 1-4%) died, 204/593 (34%, 95% CI 31-38%) required discharge to extended care facilities, including

rehabilitation services and hospice care, and 123/593 (21%, 95% CI 17-24%) were readmitted to the

160 hospital within 30 days of discharge. Universal PCR results returning prior to hospital discharge did not

significantly affect hospitalization outcomes such as mortality and discharge to rehab services compared

162 to patients whose results did not return until after discharge.

163 A positive universal PCR for fungi was significantly associated with increased hospital mortality (OR 7.65

164 [95% CI 1.80 – 32.4], p <0.05) (**Figure 3**). A positive fungal PCR result was not significantly associated

165 with discharge to rehabilitation or hospice care facilities (OR 2.38 [95% CI 1.10-5.18, p=0.052) or

readmission within 30 days following hospital discharge (OR 2.09 [95% CI 0.93-4.76], p=0.07). There

167 were no significant differences in hospital mortality, discharge to rehabilitation or hospice facilities, or

168 hospital readmission within 30 days among inpatients with positive bacterial or mycobacterial results.

169 There were no significant differences in hospitalization length of stay associated with positive results for

170 bacteria, mycobacteria, or fungi (Supplemental Figure 1).

171

172 Discussion

In this study, we examined clinical factors associated with positive universal PCR results, as well as
 associated hospitalization outcomes. In line with prior literature, we found that positive Gram stain
 results or histology results, neutrophils on Gram stain, and growth in culture were all significantly
 associated with positive universal PCR results^{25,31}.

177 Our clinicians ordered universal PCR on a wide variety of specimen types, most frequently in the case of 178 orthopedic infections. We found that although they were the most frequently ordered, orthopedic 179 specimens such as joint, bone, and intervertebral discs were among the least likely specimens to return 180 positive. While less frequently ordered, heart valves were among the highest positivity rates and most 181 frequently led to changes in antibiotic management. These findings are in line with current literature 182 demonstrating great utility of universal PCR for endocarditis, so much so that some studies have even 183 suggested that universal PCR be incorporated as part of the modified Duke's criteria for diagnosis of 184 infective endocarditis²².

185 In our cohort, 20% of all positive universal PCR results were considered contaminants by clinical teams. 186 We relied on clinical judgement about whether a positive universal PCR result represented a true 187 infection or contamination. We believe that the fraction of results considered "contaminated" was 188 actually underestimated in our data set due to clinicians potentially over-treating clinically insignificant 189 organisms detected on universal PCR out of an abundance of caution (Note, PCR disagreed with culture-190 based identification in 32% of cases). With a lack of gold standard in determining whether a resulting 191 organism is truly causative of infection, universal PCR will likely continue to produce organism 192 identifications that will present a clinical dilemma over whether to treat. 193 Among patients with positive universal PCR results, only 29% of results led to a change in antibiotic

194 management. The impact of positive universal PCR results on antibiotic management varies widely in

the literature, with studies showing a change in management in 5% to 76% of cases^{16,24,25,32}. The majority

196 of our patients were on empiric treatment prior to universal PCR results, and so clinicians must consider 197 the value that universal PCR brings to potentially changing or narrowing treatment, and how strongly 198 that will impact their patients' care. A limitation of this study is that we were unable to perform a similar 199 analysis to determine the changes in antibiotic management that may have resulted from a negative 200 universal PCR result. While positive universal PCR results were invariably acknowledged in clinician 201 notes, negative results were less frequently documented and therefore could not be directly correlated 202 with treatment decisions. This may be a fruitful topic for future work. 203 We found that positive results from universal PCR for fungi were associated with worse hospital 204 outcomes. 4/30 (13%) positive cases in hospitalized inpatients were associated with patient death, and 205 15/30 (50%) cases required discharge to extended care facilities or hospice. This finding likely reflects 206 that patients with occult fungal infections are likely to be sicker with more severe systemic illness 207 compared to patients without infections as the etiology of their disease. 208 There were no circumstances in which a positive result of universal PCR led to demonstrable 209 improvements in hospitalization outcomes. Patients with positive universal PCR results for bacteria and 210 mycobacteria did not have any change in hospital mortality, discharge to extended care facilities, 211 readmission within 30 days, or length of stay. However, our universal PCR results took an average of 12 212 days from specimen collection to result, and 76% of hospitalized patients were discharged before results 213 returned. When considering the utility of this assay, turnaround time is a critical component. With 214 improvements in turnaround time through the development of commercialized assays, it is possible that 215 earlier time to appropriate antimicrobial intervention may be able to improve hospitalization 216 outcomes^{9,13}. However, many of these patients were treated empirically with broad-range antibiotics 217 prior to results and it can be difficult to parse out specific improvements that occurred as a result of 218 potentially narrowing coverage. It can be challenging to quantify other metrics of improper antibiotic 219 use such as medication side effects, excess healthcare cost, and the promotion of resistance based on a

220	retrospective analysis. With that said, universal PCR data may also prove valuable to infection control for
221	epidemiologic studies; for example, in our hospital network, a cluster of four cases of Acinetobacter juni
222	detected in orthopedic specimens in 2022 prompted an internal infection control investigation to
223	identify potential sources of OR contamination to reduce false positive rates.
224	Further studies focused on other outcomes as outlined above are needed to fully assess the utility of
225	universal PCR for the diagnosis of occult infections. With little changes in hospitalization outcomes
226	occurring as a result of universal PCR, clinicians should carefully consider the desired outcomes of a
227	universal PCR weighed against the potential high cost of testing and the risk of over-treating organisms
228	which may not truly be causative of infection. Given the significant variation in ordering and treatment
229	practices among physicians, there will continue to be fluctuations in positivity rates and changes in
230	antimicrobial practice from institution to institution until standardized guidelines are established for the
231	use of this technology, highlighting the need for intensive studies into the utility of universal PCR in
232	clinical practice.

233

234 Acknowledgements

235 We thank the University of Washington Molecular Diagnosis Microbiology Section (Seattle, WA), our

reference laboratory to whom we sent all samples to perform universal PCR studies. We also thank our

237 clinical and laboratory staff for specimen submission and processing.

238

239 Conflicts of Interest

240 The authors have no conflicts of interest to disclose.

241

242 Author Contributions

243 J.K. and S.R. conceived the studies and established param	meters for data collection. A.M. and R.A.
---	---

- retrieved the data from our institution's clinical data repository. Data analysis was performed by J.K. and
- A.K. Manuscript was written by J.K, R.A, and S.R. All authors reviewed the manuscript, data, and
- approved the final version.
- 247

248 References

- 249 1. Church DL, Cerutti L, Gürtler A, Griener T, Zelazny A, Emler S. Performance and Application of
- 250 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology

251 Laboratory. Clin Microbiol Rev. 2020;33(4):e00053-19. doi:10.1128/CMR.00053-19

252 2. Sontakke S, Cadenas MB, Maggi RG, Diniz PPVP, Breitschwerdt EB. Use of broad range16S rDNA

253 PCR in clinical microbiology. *Journal of Microbiological Methods*. 2009;76(3):217-225.

- 254 doi:10.1016/j.mimet.2008.11.002
- 255 3. Morel AS, Dubourg G, Prudent E, et al. Complementarity between targeted real-time specific
- 256 PCR and conventional broad-range 16S rDNA PCR in the syndrome-driven diagnosis of infectious
- 257 diseases. Eur J Clin Microbiol Infect Dis. 2015;34(3):561-570. doi:10.1007/s10096-014-2263-z
- 4. Rampini SK, Bloemberg GV, Keller PM, et al. Broad-Range 16S rRNA Gene Polymerase Chain
- 259 Reaction for Diagnosis of Culture-Negative Bacterial Infections. *Clinical Infectious Diseases*.
- 260 2011;53(12):1245-1251. doi:10.1093/cid/cir692
- 261 5. Schuurman T, de Boer RF, Kooistra-Smid AMD, van Zwet AA. Prospective Study of Use of PCR
- 262 Amplification and Sequencing of 16S Ribosomal DNA from Cerebrospinal Fluid for Diagnosis of

263 Bacterial Meningitis in a Clinical Setting. *J Clin Microbiol*. 2004;42(2):734-740.

264 doi:10.1128/JCM.42.2.734-740.2004

- 265 6. Tkadlec J, Peckova M, Sramkova L, et al. The use of broad-range bacterial PCR in the diagnosis of
- infectious diseases: a prospective cohort study. *Clinical Microbiology and Infection*. 2019;25(6):747-
- 267 752. doi:10.1016/j.cmi.2018.10.001
- 268 7. Lass-Flörl C, Mutschlechner W, Aigner M, et al. Utility of PCR in Diagnosis of Invasive Fungal
- 269 Infections: Real-Life Data from a Multicenter Study. *J Clin Microbiol*. 2013;51(3):863-868.
- 270 doi:10.1128/JCM.02965-12
- 271 8. Deutch S, Pedersen LN, Pødenphant L, et al. Broad-range real time PCR and DNA sequencing for

the diagnosis of bacterial meningitis. *Scandinavian Journal of Infectious Diseases*. 2006;38(1):27-35.

- 273 doi:10.1080/00365540500372861
- 9. Welinder-Olsson C, Dotevall L, Hogevik H, et al. Comparison of broad-range bacterial PCR and
- culture of cerebrospinal fluid for diagnosis of community-acquired bacterial meningitis. *Clinical*

276 *Microbiology and Infection*. 2007;13(9):879-886. doi:10.1111/j.1469-0691.2007.01756.x

277 10. Mishra D, Satpathy G, Chawla R, Venkatesh P, Ahmed NH, Panda SK. Utility of broad-range 16S

278 rRNA PCR assay versus conventional methods for laboratory diagnosis of bacterial endophthalmitis in

- a tertiary care hospital. Br J Ophthalmol. 2019;103(1):152-156. doi:10.1136/bjophthalmol-2018-
- 280 312877
- 281 11. Ogawa M, Sugita S, Watanabe K, Shimizu N, Mochizuki M. Novel diagnosis of fungal

282 endophthalmitis by broad-range real-time PCR detection of fungal 28S ribosomal DNA. Graefes Arch

283 *Clin Exp Ophthalmol*. 2012;250(12):1877-1883. doi:10.1007/s00417-012-2015-7

284	12.	Fenollar F, Roux V, Stein A, Drancourt M, Raoult D. Analysis of 525 Samples To Determine the
285	Use	efulness of PCR Amplification and Sequencing of the 16S rRNA Gene for Diagnosis of Bone and
286	Joir	nt Infections. <i>J Clin Microbiol</i> . 2006;44(3):1018-1028. doi:10.1128/JCM.44.3.1018-1028.2006
287	13.	Kühn C, Disqué C, Mühl H, Orszag P, Stiesch M, Haverich A. Evaluation of Commercial Universal
288	rRN	IA Gene PCR plus Sequencing Tests for Identification of Bacteria and Fungi Associated with
289	Infe	ectious Endocarditis. <i>J Clin Microbiol</i> . 2011;49(8):2919-2923. doi:10.1128/JCM.00830-11
290	14.	Gille J, Wallstabe S, Schulz AP, Paech A, Gerlach U. Is non-union of tibial shaft fractures due to
291	nor	nculturable bacterial pathogens? A clinical investigation using PCR and culture techniques. J Orthop
292	Sur	g Res. 2012;7(1):20. doi:10.1186/1749-799X-7-20
293	15.	Qu X, Zhai Z, Li H, et al. PCR-Based Diagnosis of Prosthetic Joint Infection. J Clin Microbiol.
294	201	.3;51(8):2742-2746. doi:10.1128/JCM.00657-13
295	16.	Lampejo T, Ciesielczuk H, Lambourne J. Clinical utility of 16S rRNA PCR in pleural infection.
296	Jou	rnal of Medical Microbiology. 2021;70(5). doi:10.1099/jmm.0.001366
297	17.	Insa R, Marín M, Martín A, et al. Systematic Use of Universal 16S rRNA Gene Polymerase Chain
298	Rea	action (PCR) and Sequencing for Processing Pleural Effusions Improves Conventional Culture
299	Tec	hniques. <i>Medicine</i> . 2012;91(2):103-110. doi:10.1097/MD.0b013e31824dfdb0
300	18.	Lieberman JA, Bryan A, Mays JA, et al. High Clinical Impact of Broad-Range Fungal PCR in
301	Sus	pected Fungal Sinusitis. Hanson KE, ed. J Clin Microbiol. 2021;59(11):e00955-21.
302	doi	:10.1128/JCM.00955-21

303	19. Faraji R, Behjati-Ardakani M, Moshtaghioun SM, et al. The diagnosis of microorganism involved				
304	in in	fective endocarditis (IE) by polymerase chain reaction (PCR) and real-time PCR: A systematic			
305	revi	ew. <i>The Kaohsiung J of Med Scie</i> . 2018;34(2):71-78. doi:10.1016/j.kjms.2017.09.011			
306	20.	Harris KA, Yam T, Jalili S, et al. Service evaluation to establish the sensitivity, specificity and			
307	additional value of broad-range 16S rDNA PCR for the diagnosis of infective endocarditis from				
308	resected endocardial material in patients from eight UK and Ireland hospitals. Eur J Clin Microbiol				
309	9 Infect Dis. 2014;33(11):2061-2066. doi:10.1007/s10096-014-2145-4				
310	21.	Armstrong C, Kuhn TC, Dufner M, et al. The diagnostic benefit of 16S rDNA PCR examination of			
311	infective endocarditis heart valves: a cohort study of 146 surgical cases confirmed by histopathology.				
312	Clin	<i>Res Cardiol</i> . 2021;110(3):332-342. doi:10.1007/s00392-020-01678-x			
313	22.	Marín M, Muñoz P, Sánchez M, et al. Molecular Diagnosis of Infective Endocarditis by Real-Time			
314	Broa	ad-Range Polymerase Chain Reaction (PCR) and Sequencing Directly From Heart Valve Tissue.			
315	Мес	<i>dicine</i> . 2007;86(4):195-202. doi:10.1097/MD.0b013e31811f44ec			
316	23.	Kerkhoff AD, Rutishauser RL, Miller S, Babik JM. Clinical Utility of Universal Broad-Range			
317	Poly	merase Chain Reaction Amplicon Sequencing for Pathogen Identification: A Retrospective Cohort			
318	Stuc	dy. Clinical Infectious Diseases. 2020;71(6):1554-1557. doi:10.1093/cid/ciz1245			
319	24.	Marbjerg LH, Holzknecht BJ, Dargis R, Dessau RB, Nielsen XC, Christensen JJ. Commercial			
320	bact	terial and fungal broad-range PCR (Micro-Dx [™]) used on culture-negative specimens from			
321	nori	mally sterile sites: diagnostic value and implications for antimicrobial treatment. Diagnostic			
322	Mic	robiology and Infectious Disease. 2020;97(2):115028. doi:10.1016/j.diagmicrobio.2020.115028			

- 323 25. Naureckas Li C, Nakamura MM. Utility of Broad-Range PCR Sequencing for Infectious Diseases
- 324 Clinical Decision Making: a Pediatric Center Experience. McElvania E, ed. J Clin Microbiol.
- 325 2022;60(5):e02437-21. doi:10.1128/jcm.02437-21
- 326 26. Renvoisé A, Brossier F, Sougakoff W, Jarlier V, Aubry A. Broad-range PCR: Past, present, or future
- 327 of bacteriology? *Médecine et Maladies Infectieuses*. 2013;43(8):322-330.
- doi:10.1016/j.medmal.2013.06.003
- 329 27. Aggarwal D, Kanitkar T, Narouz M, Azadian BS, Moore LSP, Mughal N. Clinical utility and cost-
- effectiveness of bacterial 16S rRNA and targeted PCR based diagnostic testing in a UK microbiology
- 331 laboratory network. *Sci Rep.* 2020;10(1):7965. doi:10.1038/s41598-020-64739-1
- 332 28. Stempak LM, Vogel SA, Richter SS, Wyllie R, Procop GW. Routine Broad-Range Fungal
- Polymerase Chain Reaction With DNA Sequencing in Patients With Suspected Mycoses Does Not Add
- Value and Is Not Cost-Effective. *Archives of Pathology & Laboratory Medicine*. 2019;143(5):634-638.
- 335 doi:10.5858/arpa.2017-0299-OA
- 336 29. Miller K, Harrington SM, Procop GW. Acid-fast Smear and Histopathology Results Provide
- 337 Guidance for the Appropriate Use of Broad-Range Polymerase Chain Reaction and Sequencing for
- 338 Mycobacteria. *Archives of Pathology & Laboratory Medicine*. 2015;139(8):1020-1023.
- 339 doi:10.5858/arpa.2013-0705-OA
- 340 30. Panousis K, Grigoris P, Butcher I, Rana B, Reilly JH, Hamblen DL. Poor predictive value of broad-
- range PCR for the detection of arthroplasty infection in 92 cases. Acta Orthopaedica. 2005;76(3):341-
- 342 346. doi:10.1080/00016470510030805

343	31. Basein, Tinzar, Gardiner, Bradley, Andujar-Vazquez, Gabriela, et al. Clinical Utility of Universal
344	PCR and its Real-world Impact on Patient Management. In: IDSA Stewardship: Impact of Diagnostics.
345	Vol 4. ; 2017:S627.
346	32. Racsa LD, DeLeon-Carnes M, Hiskey M, Guarner J. Identification of bacterial pathogens from
347	formalin-fixed, paraffin-embedded tissues by using 16S sequencing: retrospective correlation of
348	results to clinicians' responses. Human Pathology. 2017;59:132-138.

doi:10.1016/j.humpath.2016.09.015

350

351







354 **Figure 1.** Total number of specimens sent for universal PCR and positivity rate by pathogen type (A) and

- by specimen source (B). A single specimen could be sent for more than one universal PCR at a time.
- 356 Error bars represent the 95% population proportion confidence intervals for positive results.



- 358 **Figure 2.** Management decisions made by the clinical team based on positive universal PCR results by
- 359 pathogen type (A) and by specimen source (B). Error bars represent the 95% population proportion
- 360 confidence intervals for positive results. Antimicrobial course was not changed in the case of death,
- 361 transition to comfort care, patient improvement without intervention, satisfactory empiric treatment, or
- 362 presumed contamination of universal PCR sample.



363

- **Figure 3.** Hospitalization outcomes following positive universal PCR results compared to specimens
- 365 which were negative via universal PCR. Error bars represent the 95% confidence interval around the

366 odds ratio.

Table 1. Pre-analytic determinants of positive universal PCR results.

	Total specimens	Total positives by universal PCR	Percent positive (95% Cls)	Corrected p value
Total	708	163	23% (20-26%)	
Female Gender	342	73	21% (17-26%)	0.81
Age > 50	498	113	23% (19-26%)	0.97
Hardware Present	160	35	22% (15-28%)	0.97
Gram stain organisms present	44	23	52% (38-67%)	0.0001
Neutrophils absent on gram stain	178	29	16% (11-22%)	0.021
Cultures positive	154	53	34% (27-42%)	0.016
Organisms seen on histology	73	34	47% (35-58%)	0.0001
Granuloma on histology	72	12	17% (8-25%)	0.42
Formalin fixed tissue	68	22	32% (21-43%)	0.20
Outpatient	115	27	23% (16-31%)	0.97
Inpatient	593	136	23% (20-26%)	0.97

368